Biomarkers in dementia: clinical utility and new directions

• Imaging, cerebrospinal fluid (CSF) and blood-based biomarkers have the potential to improve the accuracy by which specific causes of dementia can be diagnosed in vivo, provide insights into the underlying pathophysiology, and may be used as inclusion criteria and outcome measures for clinical trials. While a number of imaging and CSF biomarkers are currently used for each of these purposes, this is an evolving field, with numerous potential biomarkers in varying stages of research and development. We review the currently available biomarkers for the three most common forms of neurodegenerative dementia, and give an overview of research techniques that may in due course make their way into the clinic.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Psykiatri (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Psychiatry (hsv//eng)

Nyckelord

FRONTOTEMPORAL LOBAR DEGENERATION

MILD COGNITIVE IMPAIRMENT

ALZHEIMERS

ASSOCIATION WORKGROUPS

PRIMARY-PROGRESSIVE-APHASIA

POSITRON-EMISSION-TOMOGRAPHY

CEREBROSPINAL-FLUID S100B

VOXEL-BASED

MORPHOMETRY

LEWY BODIES

BEHAVIORAL VARIANT

CSF BIOMARKERS

Publikations- och innehållstyp

ref (ämneskategori)

art (ämneskategori)